Scinai Return On Assets from 2010 to 2026

SCNI Stock  USD 0.83  0.08  10.67%   
Scinai Immunotherapeuti's Return On Assets are increasing with slightly volatile movements from year to year. Return On Assets are estimated to finish at 0.34 this year. Return On Assets is a profitability ratio that indicates the percentage of profit Scinai Immunotherapeutics earns in relation to its overall resources. It is calculated by dividing net income by total assets. View All Fundamentals
 
Return On Assets  
First Reported
2010-12-31
Previous Quarter
0.32
Current Value
0.34
Quarterly Volatility
0.35397095
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Scinai Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scinai Immunotherapeuti's main balance sheet or income statement drivers, such as Interest Expense of 1 M, Selling General Administrative of 4.2 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 3.29, Dividend Yield of 0.0 or PTB Ratio of 0.23. Scinai financial statements analysis is a perfect complement when working with Scinai Immunotherapeuti Valuation or Volatility modules.
  
Build AI portfolio with Scinai Stock
Check out the analysis of Scinai Immunotherapeuti Correlation against competitors.

Latest Scinai Immunotherapeuti's Return On Assets Growth Pattern

Below is the plot of the Return On Assets of Scinai Immunotherapeutics over the last few years. It is a profitability ratio that indicates the percentage of profit a company earns in relation to its overall resources. It is calculated by dividing net income by total assets. Scinai Immunotherapeuti's Return On Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Scinai Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
Return On Assets10 Years Trend
Slightly volatile
   Return On Assets   
       Timeline  

Scinai Return On Assets Regression Statistics

Arithmetic Mean(0.26)
Geometric Mean0.34
Coefficient Of Variation(135.14)
Mean Deviation0.24
Median(0.31)
Standard Deviation0.35
Sample Variance0.13
Range1.3
R-Value0.52
Mean Square Error0.1
R-Squared0.28
Significance0.03
Slope0.04
Total Sum of Squares2.00

Scinai Return On Assets History

2026 0.34
2025 0.32
2024 0.36
2023 -0.37
2022 -0.21
2021 -0.26
2020 -0.0783

About Scinai Immunotherapeuti Financial Statements

Investors use fundamental indicators, such as Scinai Immunotherapeuti's Return On Assets, to determine how well the company is positioned to perform in the future. Although Scinai Immunotherapeuti's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Return On Assets 0.32  0.34 

Currently Active Assets on Macroaxis

When determining whether Scinai Immunotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scinai Immunotherapeuti's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scinai Immunotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scinai Immunotherapeutics Stock:
Check out the analysis of Scinai Immunotherapeuti Correlation against competitors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Semiconductors & Semiconductor Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scinai Immunotherapeuti. If investors know Scinai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scinai Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.872
Earnings Share
4
Quarterly Revenue Growth
0.361
Return On Assets
(0.40)
Return On Equity
0.1792
The market value of Scinai Immunotherapeutics is measured differently than its book value, which is the value of Scinai that is recorded on the company's balance sheet. Investors also form their own opinion of Scinai Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Scinai Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scinai Immunotherapeuti's market value can be influenced by many factors that don't directly affect Scinai Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scinai Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scinai Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scinai Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.